IP02-34 TREATMENT OF RECURRENT NON-MUSCLE INVASIVE BLADDER CANCER WITH UGN-301 (ZALIFRELIMAB): RESULTS OF A PHASE 1 DOSE-ESCALATION STUDY | Publicación